Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001711279-25-000044
Filing Date
2025-05-06
Accepted
2025-05-06 08:08:58
Documents
68
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q krys-20250331.htm   iXBRL 10-Q 1305013
2 EX-31.1 a1q25krysex311.htm EX-31.1 10906
3 EX-31.2 a1q25krysex312.htm EX-31.2 10868
4 EX-32.1 a1q25krysex321.htm EX-32.1 11150
  Complete submission text file 0001711279-25-000044.txt   6256338

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT krys-20250331.xsd EX-101.SCH 38977
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT krys-20250331_cal.xml EX-101.CAL 65710
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT krys-20250331_def.xml EX-101.DEF 169261
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT krys-20250331_lab.xml EX-101.LAB 546069
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT krys-20250331_pre.xml EX-101.PRE 366269
71 EXTRACTED XBRL INSTANCE DOCUMENT krys-20250331_htm.xml XML 859170
Mailing Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203
Business Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203 (412) 586-5830
Krystal Biotech, Inc. (Filer) CIK: 0001711279 (see all company filings)

EIN.: 821080209 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38210 | Film No.: 25915330
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)